Retrospective Cohort Study
Copyright ©The Author(s) 2020.
World J Gastrointest Oncol. Apr 15, 2020; 12(4): 405-423
Published online Apr 15, 2020. doi: 10.4251/wjgo.v12.i4.405
Table 1 Patient characteristics before propensity score matching
LPTL1
RPTL1
Cetuximab (n = 164)Bevacizumab (n = 679)P valueCetuximab (n = 84)Bevacizumab (n = 385)P value
Age at index date2, years0.7270.801
Median61.061.066.567.0
Sex, n (%)0.7490.296
Female59 (36.0)256 (37.7)36 (42.9)192 (49.9)
Male105 (64.0)423 (62.3)48 (57.1)193 (50.1)
Race, n (%)0.0420.506
Black or African American17 (10.4)61 (9.0)7 (8.3)43 (11.2)
White114 (69.5)435 (64.1)57 (67.9)264 (68.6)
Other race27 (16.5)109 (16.1)9 (10.7)46 (11.9)
Missing6 (3.7)74 (10.9)11 (13.1)32 (8.3)
Region, n (%)0.0010.008
Northeast38 (23.2)144 (21.2)20 (23.8)73 (19.0)
Midwest14 (8.5)133 (19.6)12 (14.3)99 (25.7)
South54 (32.9)246 (36.2)24 (28.6)140 (36.4)
West40 (24.4)105 (15.5)15 (17.9)47 (12.2)
Unknown18 (11.0)51 (7.5)13 (15.5)26 (6.8)
Practice type, n (%)0.0790.052
Academic2 (1.2)31 (4.6)017 (4.4)
Community162 (98.8)648 (95.4)84 (100)368 (95.6)
Site of disease, n (%)1.000NA
Colon111 (67.7)460 (67.7)84 (100)385 (100)
Rectum53 (32.3)219 (32.3)00
Side of colon, n (%)0.9730.745
Left side86 (52.4)364 (53.6)00
Rectosigmoid18 (11.0)79 (11.6)00
Rectum52 (31.7)206 (30.3)00
Splenic flexure8 (4.9)30 (4.4)00
Right side0070 (83.3)329 (85.5)
Transverse colon0014 (16.7)56 (14.5)
Group stage at initial diagnosis, n (%)0.1990.001
Stage I2 (1.2)26 (3.8)1 (1.2)5 (1.3)
Stage II13 (7.9)73 (10.8)5 (6.0)40 (10.4)
Stage III44 (26.8)145 (21.4)37 (44.0)87 (22.6)
Stage IV101 (61.6)411 (60.5)41 (48.8)253 (65.7)
Unknown4 (2.4)24 (3.5)00
ECOG PS at index date2, 3, n (%)0.1760.026
039 (23.8)192 (28.3)27 (32.1)80 (20.8)
122 (13.4)117 (17.2)9 (10.7)83 (21.6)
2+5 (3.0)29 (4.3)3 (3.6)26 (6.8)
Missing98 (59.8)341 (50.2)45 (53.6)196 (50.9)
Modified CCI at index date2, 4, n (%)0.5260.339
0136 (82.9)557 (82.0)64 (76.2)293 (76.1)
120 (12.2)86 (12.7)17 (20.2)59 (15.3)
27 (4.3)21 (3.1)3 (3.6)24 (6.2)
3+1 (0.6)15 (2.2)09 (2.3)
NRAS tested, n (%)51 (31.1)281 (41.4)0.02028 (33.3)160 (41.6)0.204
NRAS status among those tested5, n (%)0.1120.373
Mutation negative49 (96.1)256 (91.1)28 (100)144 (90.0)
Mutation positive019 (6.8)014 (8.8)
Results pending01 (0.4)01 (0.6)
Unknown1 (2.0)1 (0.4)00
Unsuccessful/indeterminate1 (2.0)4 (1.4)01 (0.6)
BRAF tested, n (%)46 (28.0)313 (46.1)< 0.00135 (41.7)176 (45.7)0.579
BRAF status among those tested5, n (%)0.0750.072
Mutation negative45 (97.8)288 (92.0)24 (68.6)103 (58.5)
Mutation positive023 (7.3)10 (28.6)73 (41.5)
Results pending01 (0.3)00
Unknown1 (2.2)1 (0.3)00
Unsuccessful/indeterminate001 (2.9)0
First-line chemotherapy backbone, n (%)< 0.001< 0.001
FOLFIRI105 (64.0)165 (24.3)64 (76.2)96 (24.9)
FOLFOX59 (36.0)514 (75.7)20 (23.8)289 (75.1)
History of adjuvant chemotherapy6, n (%)0.171< 0.001
No/not documented114 (69.5)510 (75.1)44 (52.4)299 (77.7)
Yes50 (30.5)169 (24.9)40 (47.6)86 (22.3)
First-line therapy duration7, days0.0760.969
Median197.0183.0156.0162.0
Length of follow-up8, days0.0190.345
Median501.5442.0323.5350.0